Concepedia

Angelina Bisconte

AB

Statistics

Publications

10

Citations

867

H-Index

10

Active since

2003

Affiliations

Principia Biopharma (United States)(Current)

University of California, Davis

University of California, San Francisco

Angelina Bisconte is an author at Principia Biopharma (United States) specializing in medicine, drug discovery, and pharmacology.

Top concepts

Publications per year

2003–2022

10

Publications

10

Prolonged and tunable residence time using reversible covalent kinase inhibitors

J. Michael Bradshaw, Jesse M. McFarland, Ville O. Paavilainen et al. · Nature Chemical Biology · 2015 · 422 citations · Full text

, , +5

Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Claire L. Langrish, J. Michael Bradshaw, Michelle Francesco et al. · The Journal of Immunology · 2021 · 108 citations · Full text

Discovery of Reversible Covalent Bruton’s Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib)

Timothy D. Owens, Ken A. Brameld, Erik Verner et al. · Journal of Medicinal Chemistry · 2022 · 65 citations · Full text

Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma

Maarja‐Liisa Nairismägi, Mary E. Gerritsen, Z. M. Li et al. · Leukemia · 2018 · 56 citations · Full text

Potent and selective inhibitors of PI3Kδ: Obtaining isoform selectivity from the affinity pocket and tryptophan shelf

Daniel P. Sutherlin, Stewart Baker, Angelina Bisconte et al. · Bioorganic & Medicinal Chemistry Letters · 2012 · 50 citations · Full text

, , +8

1–5 of 10